The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Thalassemia is a blood disorder passed down through families (inherited) in which the body makes an abnormal form or inadequate amount of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. The disorder results in large numbers of red blood cells being destroyed, which leads to anemia.
The global Thalassemia market was valued at US$ 3014.5 million in 2023 and is anticipated to reach US$ 5386 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Thalassemia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Thalassemia.
Report Scope
The Thalassemia market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Thalassemia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Thalassemia companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company (Partial List):
- Bluebird bio, Inc.
- Acceleron Pharma, Inc.
- Celgene Corporation
- GlaxoSmithKline plc
- Incyte Corporation
- Gamida Cell
- Kiadis Pharma
- La Jolla Pharmaceutical Company
- IONIS Pharmaceuticals
Segment by Type
- Iron Chelating Drugs
- Others
Segment by Application
- Hospital
- Clinic
- Research Institute
- Laboratories
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Thalassemia companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Thalassemia Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Iron Chelating Drugs
1.2.3 Others
1.3 Market by Application
1.3.1 Global Thalassemia Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Laboratories
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Thalassemia Market Perspective (2019-2030)
2.2 Thalassemia Growth Trends by Region
2.2.1 Global Thalassemia Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Thalassemia Historic Market Size by Region (2019-2024)
2.2.3 Thalassemia Forecasted Market Size by Region (2025-2030)
2.3 Thalassemia Market Dynamics
2.3.1 Thalassemia Industry Trends
2.3.2 Thalassemia Market Drivers
2.3.3 Thalassemia Market Challenges
2.3.4 Thalassemia Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Thalassemia Players by Revenue
3.1.1 Global Top Thalassemia Players by Revenue (2019-2024)
3.1.2 Global Thalassemia Revenue Market Share by Players (2019-2024)
3.2 Global Thalassemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Thalassemia Revenue
3.4 Global Thalassemia Market Concentration Ratio
3.4.1 Global Thalassemia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Thalassemia Revenue in 2023
3.5 Thalassemia Key Players Head office and Area Served
3.6 Key Players Thalassemia Product Solution and Service
3.7 Date of Enter into Thalassemia Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Thalassemia Breakdown Data by Type
4.1 Global Thalassemia Historic Market Size by Type (2019-2024)
4.2 Global Thalassemia Forecasted Market Size by Type (2025-2030)
5 Thalassemia Breakdown Data by Application
5.1 Global Thalassemia Historic Market Size by Application (2019-2024)
5.2 Global Thalassemia Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Thalassemia Market Size (2019-2030)
6.2 North America Thalassemia Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Thalassemia Market Size by Country (2019-2024)
6.4 North America Thalassemia Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Thalassemia Market Size (2019-2030)
7.2 Europe Thalassemia Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Thalassemia Market Size by Country (2019-2024)
7.4 Europe Thalassemia Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Thalassemia Market Size (2019-2030)
8.2 Asia-Pacific Thalassemia Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Thalassemia Market Size by Region (2019-2024)
8.4 Asia-Pacific Thalassemia Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Thalassemia Market Size (2019-2030)
9.2 Latin America Thalassemia Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Thalassemia Market Size by Country (2019-2024)
9.4 Latin America Thalassemia Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Thalassemia Market Size (2019-2030)
10.2 Middle East & Africa Thalassemia Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Thalassemia Market Size by Country (2019-2024)
10.4 Middle East & Africa Thalassemia Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bluebird bio, Inc.
11.1.1 Bluebird bio, Inc. Company Detail
11.1.2 Bluebird bio, Inc. Business Overview
11.1.3 Bluebird bio, Inc. Thalassemia Introduction
11.1.4 Bluebird bio, Inc. Revenue in Thalassemia Business (2019-2024)
11.1.5 Bluebird bio, Inc. Recent Development
11.2 Acceleron Pharma, Inc.
11.2.1 Acceleron Pharma, Inc. Company Detail
11.2.2 Acceleron Pharma, Inc. Business Overview
11.2.3 Acceleron Pharma, Inc. Thalassemia Introduction
11.2.4 Acceleron Pharma, Inc. Revenue in Thalassemia Business (2019-2024)
11.2.5 Acceleron Pharma, Inc. Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Detail
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Thalassemia Introduction
11.3.4 Celgene Corporation Revenue in Thalassemia Business (2019-2024)
11.3.5 Celgene Corporation Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Detail
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Thalassemia Introduction
11.4.4 GlaxoSmithKline plc Revenue in Thalassemia Business (2019-2024)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 Incyte Corporation
11.5.1 Incyte Corporation Company Detail
11.5.2 Incyte Corporation Business Overview
11.5.3 Incyte Corporation Thalassemia Introduction
11.5.4 Incyte Corporation Revenue in Thalassemia Business (2019-2024)
11.5.5 Incyte Corporation Recent Development
11.6 Gamida Cell
11.6.1 Gamida Cell Company Detail
11.6.2 Gamida Cell Business Overview
11.6.3 Gamida Cell Thalassemia Introduction
11.6.4 Gamida Cell Revenue in Thalassemia Business (2019-2024)
11.6.5 Gamida Cell Recent Development
11.7 Kiadis Pharma
11.7.1 Kiadis Pharma Company Detail
11.7.2 Kiadis Pharma Business Overview
11.7.3 Kiadis Pharma Thalassemia Introduction
11.7.4 Kiadis Pharma Revenue in Thalassemia Business (2019-2024)
11.7.5 Kiadis Pharma Recent Development
11.8 La Jolla Pharmaceutical Company
11.8.1 La Jolla Pharmaceutical Company Company Detail
11.8.2 La Jolla Pharmaceutical Company Business Overview
11.8.3 La Jolla Pharmaceutical Company Thalassemia Introduction
11.8.4 La Jolla Pharmaceutical Company Revenue in Thalassemia Business (2019-2024)
11.8.5 La Jolla Pharmaceutical Company Recent Development
11.9 IONIS Pharmaceuticals
11.9.1 IONIS Pharmaceuticals Company Detail
11.9.2 IONIS Pharmaceuticals Business Overview
11.9.3 IONIS Pharmaceuticals Thalassemia Introduction
11.9.4 IONIS Pharmaceuticals Revenue in Thalassemia Business (2019-2024)
11.9.5 IONIS Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
